-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Platinum therapy is one of the most common chemotherapy strategies for a variety of solid cancers, including lung cancer
.
The treatment strategy of cisplatin combined with radiotherapy has been used in the treatment of advanced lung cancer
Platinum therapy is one of the most common chemotherapy strategies for a variety of solid cancers, including lung cancer
Side effects and drug resistance are two major challenges that limit the application of cisplatin and the response to treatment
.
Increasing evidence shows that the levels of STAT3, MEK1, and AKT are often dysregulated in cisplatin-resistant cancers
miRNA is an endogenous non-coding RNA that contains less than 25 nucleotides
.
miRNA can bind to the 3'-UTR (3'-untranslated region) of the target mRNA, and ultimately lead to the degradation and inhibition of the mRNA
miRNA is an endogenous non-coding RNA that contains less than 25 nucleotides
The expression of miR-526b-3p decreases in cisplatin-resistant lung cancer
The expression of miR-526b-3p decreases in cisplatin-resistant lung cancerMore and more studies have shown that PD-L1 plays a vital role in regulating the cisplatin resistance of lung cancer
.
However, the underlying molecular mechanism remains unclear
PD-L1 plays a vital role in regulating the cisplatin resistance of lung cancer
Overexpression of STAT3 can reverse the inhibitory effect of miR-526b-3p in cancer metastasis
Overexpression of STAT3 can reverse the inhibitory effect of miR-526b-3p in cancer metastasisAll in all, the results of this study reveal a new mechanism of PD-L1 mediated lung cancer resistance to cisplatin
.
In addition, miR-526b-3p may provide new clues for improving the anti-tumor effect of the combination of immunotherapy and chemotherapy
The results of this study reveal a new mechanism of PD-L1-mediated lung cancer resistance to cisplatin
Chen, Kb.
, Yang, W.
, Xuan, Y.
et al.
miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.
Cell Death Dis 12, 748 (28 July 2021) .
Leave a message here